TRACON Pharmaceuticals, Inc. (NASDAQ:TCON – Get Rating) major shareholder Opaleye Management Inc. acquired 174,508 shares of the business’s stock in a transaction dated Thursday, March 9th. The shares were bought at an average cost of $1.38 per share, for a total transaction of $240,821.04. Following the transaction, the insider now directly owns 4,324,508 shares of the company’s stock, valued at approximately $5,967,821.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Opaleye Management Inc. also recently made the following trade(s):
- On Wednesday, December 14th, Opaleye Management Inc. bought 167,500 shares of TRACON Pharmaceuticals stock. The shares were bought at an average cost of $1.25 per share, with a total value of $209,375.00.
TRACON Pharmaceuticals Stock Up 2.1 %
NASDAQ TCON opened at $1.46 on Tuesday. TRACON Pharmaceuticals, Inc. has a 52-week low of $1.10 and a 52-week high of $2.90. The firm has a 50-day moving average price of $1.63 and a 200 day moving average price of $1.63. The stock has a market capitalization of $34.78 million, a P/E ratio of -1.04 and a beta of 1.33.
Institutional Trading of TRACON Pharmaceuticals
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Robert W. Baird cut their target price on shares of TRACON Pharmaceuticals from $10.00 to $8.00 in a research note on Thursday, December 15th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of TRACON Pharmaceuticals in a report on Thursday, March 9th. Finally, StockNews.com started coverage on TRACON Pharmaceuticals in a report on Monday, March 6th. They issued a “hold” rating on the stock.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma.
- Get a free copy of the StockNews.com research report on TRACON Pharmaceuticals (TCON)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.